FDA approves Angiotech's Hemo-Stream

Angiotech has added one more brick to its stable of end stage renal disease treatment products. The company today got FDA clearance to sell a chronic dialysis catheter it licensed from Rex Medical in April. Known as Hemo-Stream, the catheter is designed to increase flow rates and cut the risk of complications such as embolism and bleeding.

Angiotech previously acquired a related vascular graft business, and it's enrolling for European trials of its Vascular Wrap AV product, a drug-coated device designed to keep permanent dialysis access points open.

- read the release for more info

Related Articles:
Angiotech buys Quill Medical. Report
CombinatoRx gains $7M from extended Angiotech pact. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.